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Background: Interstitial lung disease (ILD) is a common extramuscular manifestation of the
idiopathic inflammatory myopathies (IIMs), dermatomyositis (DM) and polymyositis (PM). Pa-
tients with antisynthetase antibodies (ASA) demonstrate some or all of the features of the1 410 955 0036.
(S.K. Danoff).
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hts reserved.
Antisynthetase antibodies and myositis-associated ILD 1543Antisynthetase
syndromeantisynthetase syndrome including IIM and ILD. It has been hypothesized that the clinical
expression of antisynthetase syndrome varies between specific ASAs.
Objective: We sought to determine whether the myositis-associated ILD (MA-ILD) phenotype
differs based on the presence of ASAs and by ASA subtype.
Methods: A cross-sectional and longitudinal analysis of consecutive patients enrolled at the
Johns Hopkins Myositis Center with ILD in the setting of clinically diagnosed autoimmune
myositis was conducted.
Results: Seventy-seven subjects were included; 36 were ASA negative, 28 were anti-Jo1 posi-
tive, and 13 were non-Jo1 ASA positive (5 anti-PL-12, 4 anti-PL-7, 2 anti-EJ, and 2 anti-OJ).
Non-Jo1 ASA positive participants were more likely to be African-American than Caucasian
as compared to both the anti-Jo1 positive (p Z 0.01) and ASA negative groups (p < 0.01).
ASA negative participants had better mean forced vital capacity percent predicted (FVC%)
and total computed tomography scores over time compared to those with anti-Jo1 after con-
trolling for potential confounders.
Conclusions: ASA status was significantly different by race. Those with anti-Jo1 antibodies had
worse lung function and CT scores over time compared to those without detectable antisynthe-
tase antibodies. Further prospective study in a larger cohort is needed to determine whether
these apparent antibody-specific differences in demographics and manifestations of disease
translate into meaningful disparities in clinical outcomes.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Antisynthetase syndrome, the presence of idiopathic in-
flammatory myopathy in the setting of a positive anti-
synthetase antibody titer affects approximately 300,000
persons worldwide [1,2]. As initially described [3], the
myositis of antisynthetase syndrome is variably accompa-
nied by other non-myopathic manifestations [4], most
notably, highly-morbid interstitial lung disease (ILD) in up
to 75e86% of cases [5,6]. When present, ILD is estimated to
confer an excess 5-year mortality upwards of 45%, making it
the defining clinical feature of the disease with respect to
both morbidity and mortality [7].
Antisynthetase antibodies (ASA) are autoantibodies
directed against specific aminoacyl-tRNA synthetases,
which serve as integral components in protein translation.
Each of the 20 amino acids has a unique aminoacyl-tRNA
synthetase. To date, antibodies have been identified
against 8 unique aminoacyl-tRNA synthetases including Jo1
(histidyl), PL-7 (threonyl), PL-12 (alanyl), EJ (glycyl), OJ
(isoleucyl), KS (asparginyl), Zo (phenylalanyl), and Tyr
(tryosyl). Antisynthetase autoantibodies are very specific
for myositis and are not seen at any frequency in the gen-
eral population [8e10]. The most common antisynthetase
antibody, anti-Jo1, is associated with 25e38% of cases of
antisynthetase syndrome [11e13]. The remaining ASAs are
less well characterized. Further, some patients with clinical
manifestations consistent with antisynthetase syndrome
are “antibody negative”. This may represent a group of
patients with myositis-associated interstitial lung disease
(MA-ILD) and no autoantibody or possibly a heterogeneous
group of patients with as-yet-unidentified ASAs. It is not
known whether the pulmonary phenotype in antisynthetase
syndrome varies as a function of the presence or absence of
a specific antisynthetase antibody.The Johns Hopkins Myositis Center, established in 2007,
provides integrated multi-disciplinary care for patients with
myositis. Over 750 patients with idiopathic inflammatory
myopathies have been evaluated with records dating back
to 1995, including approximately 20% who have concurrent
pulmonary disease. Our aim in this retrospective analysis is
to describe the clinical characteristics by antisynthetase
antibody status, seen in this cohort.Methods
Study population
This study was approved by the Institutional Review Board
of the Johns Hopkins University School of Medicine. We
queried the electronic medical records from January 1995
to December 2009 of patients evaluated at the Johns
Hopkins Myositis Center. Eligibility criteria were as follows:
possible, probable, or definite diagnosis of idiopathic in-
flammatory myopathy (specifically polymyositis [PM], der-
matomyositis [DM], or myositis overlap syndrome based on
Bohan and Peter criteria [14,15]), an established diagnosis
of interstitial lung disease based on the American Thoracic
Society (ATS) guidelines [16], and at least 6 months of
clinical follow-up time at Johns Hopkins.
Clinical measures
Data obtained included demographic information (age,
gender and race by self-identification), inflammatory
myopathy subtype (DM, PM, or an inflammatory myositis
presenting with clinical overlap with another autoimmune
condition), antisynthetase antibody status, pulmonary
function test and chest computed tomography (CT) data
1544 C. Johnson et al.both at the time of diagnosis with ILD as well as at the most
recent follow up visit, and lung biopsy information when
available.
All patients were tested for antisynthetase antibodies.
ASAs were assayed by the RDL Reference Laboratory (10755
Venice Blvd. Los Angeles, CA 90034) or by the Johns Hopkins
Rheumatic Disease Research Core Center using previously
validated methods of immunoprecipitation. Participants
with other known myositis specific autoantibodies, but
without a clinically available antisynthetase antibody, were
considered antisynthetase antibody negative. Of note, an-
tibodies to melanoma differentiation-associated protein 5
(MDA5) were not included in this study since the assay was
unavailable at the time.
Pulmonary function testing (PFT) included spirometry,
lung volumes measured by helium dilution, and diffusing
capacity by single breath carbon monoxide based on ATS
criteria. [17]
All patients had baseline high resolution CT (HRCT) scans
(1 mm slice thickness), which were performed at a number
of centers. Follow-up HRCT scans were obtained only when
clinically necessary. Scans performed at Johns Hopkins or
with images uploaded into our system were scored for the
cross-sectional and longitudinal analyses by a single blinded
investigator using a previously-validated, standardized
scoring system [18,19]. All scans were scored bilaterally by
lung zone (upper, middle, lower) in each of four categories:
honeycombing, interstitial thickening, interstitial fibrosis,
and ground glass on a scale of 1e3. Results of the honey-
combing, interstitial thickening, and interstitial fibrosis
scores were combined into the category “fibrosis” for our
purposes. A total CT score was also calculated by adding the
fibrosis score (maximum possible scoreZ 54) to the ground
glass score (maximum possible score Z 18). Grading of
severity for fibrosis is as follows: 0 Z no fibrosis,
1e18 Z mild fibrosis, 19e36 Z moderate fibrosis,
37 Z severe fibrosis. Grading for severity of ground glass
is as follows: 0Z no ground glass, 1e6Zmild ground glass,
7e12 Z moderate ground glass,  13 Z severe ground
glass. The total CT scan score grading is as follows: 0 Z no
disease, 1e24Z mild disease, 25e48Z moderate disease,
and 49 Z severe disease.
Surgical lung biopsies where obtained only when deemed
clinically warranted by the treating or referring clinician.
The Johns Hopkins Surgical Pathology Department recom-
mends targeting at least two lobes with areas of active
ground glass on the most recent HRCT with specimens of at
least 4 cm in greatest dimension when inflated. Some bi-
opsy specimens were obtained outside from institutions
where protocols may differ. To maximize the consistency of
surgical lung biopsy results, only biopsy specimens that
were interpreted by pathologists at our center were
included in the analysis.Statistical analysis
All statistical analyses were performed using Stata v.12.1
(Stata Corp., College Station Texas). Descriptive statistics
were generated from baseline data. Fisher’s exact test was
used to compare categorical variable frequencies between
antibody subtypes. Simple linear regression was used tocompare unadjusted group means for continuous variables.
For the longitudinal data analyses, we analyzed each
outcome using a general linear model with correlated er-
rors that considered time as a continuous variable. These
models used weighted least-squares to generate estimates
for the mean forced vital capacity percent predicted (FVC
%), carbon monoxide diffusing capacity percent predicted
(DLCO%), or total CT score as a function of time. We chose
to model FVC% and DLCO% since these values are accepted
measures of disease progression in patients with ILD.
Restricted maximum likelihood estimation of the covari-
ance parameters was used to provide robust inferences in
the event of covariance structure misspecification. In each
model exponential correlation was used to model the
covariance structure among the repeat measures by sub-
ject. We chose this structure due to irregularly spaced
follow-up measurements between subjects. All available
data were used for the analyses; the data were assumed to
be missing at random. A p value of <0.05 was used as the
cutoff for statistical significance; estimates of uncertainty
were presented as 95 percent confidence intervals (95% CI).
Results
Baseline characteristics
Demography and clinical features
Seventy-seven subjects met all inclusion criteria and were
analyzed in our study; baseline participant characteristics
are summarized in Table 1. Thirty-six were ASA negative, 28
had anti-Jo1 antisynthetase antibodies, and 13 were non-
Jo1 ASA positive (5 anti-PL-12, 4 anti-PL-7, 2 anti-EJ, and
2 anti-OJ). Most participants were Caucasian women. There
was no statistically significant difference in the mean age,
gender, myopathy subtype, or presenting symptom among
the different antibody subtypes. Although African-
Americans made up only 36% of the cohort, participants
who were non-Jo1 ASA positive were more likely to be
African-American than Caucasian/Other as compared to
both the anti-Jo1 positive (p Z 0.01) and ASA negative
groups (p < 0.01) (Fig. 1).
Pulmonary physiology
All subjects had baseline pulmonary function testing.
Taken together, the cohort demonstrated moderate
restrictive and gas transfer defects at the time of
diagnosis (mean FVC% Z 64%, mean TLC% Z 67%, mean
DLCO% Z 58%). There was no significant difference in
baseline mean FVC% or DLCO% based on ASA subtype. The
cohort displayed significant heterogeneity in unadjusted
lung function between the initial and follow-up visit with
worsening disease (defined by a  5% drop in FVC%) in 40%
of the participants, no change in 16%, and improvement
(a  5% increase in FVC%) in 44% of participants. There was
no significant difference in the proportion of those who
worsened, improved, or remained the same based on ASA
status (p Z 0.72).
Chest CT findings
CT scan data was available for scoring in 65 (85%) subjects.
The median length of time between CT scans was 18 months
Table 1 Baseline participant characteristics, by antisynthetase antibody.a
ASA negative
(n Z 36)
Anti-Jo1
(n Z 28)
Anti-PL-7
(n Z 4)
Anti-PL-12
(n Z 5)
Anti-EJ
(n Z 2)
Anti-OJ
(n Z 2)
Demographics N/77
Mean age 51 53 56 50 67 36
Women 22 (61) 22 (79) 4 (100) 4 (80) 1 (50) 1 (50)
Race
Caucasian 25 (69) 19 (68) 1 (25) e 2 (100) e
African-American 9 (25) 9 (32) 3 (75) 5 (100) e 2 (100)
Other 2 (6) e e e e e
Clinical features 77
Myopathy subtype
Dermatomyositis 9 (25) 9 (32) e e e e
Polymyositis 12 (33) 10 (32) 4 (100) 3 (60) 2 (100) 1 (50)
Overlap syndrome 15 (42) 9 (32) e 2 (40) e 1 (50)
Presenting symptom
Shortness of breath 14 (39) 12 (43) 4 (100) 4 (80) 1 (50) e
Weakness 4 (11) 5 (18) e 1 (20) e 1 (50)
Fatigue 2 (6) 4 (14) e e e 1 (50)
Pain 7 (19) 6 (21) e e 1 (50) e
Dermatologic findings 9 (25) 1 (4) e e e e
Pulmonary physiology 77
Mean FVC, % predicted 68.0 63.9 57.5 48.0 73.8 34.6
Mean DLCO, % predicted 62.8 57.6 54.4 43.6 56.0 35.7
Chest CT scores 49
Mean Fibrosis Score 11 13 19 36 4 12
Mean ground glass score 8 7 10 12 8 10
Mean total CT Score 18 21 29 48 12 22
Biopsy findings 32
OP 5 (36) 4 (50) 1 (33.3) 1 (20) e e
NSIP 4 (29) 4 (50) 1 (33.3) 1 (20) e e
UIP 4 (29) e 1 (33.3) 3 (60) e 2 (100)
Unclassifiable 1 (6) e e e e e
ASA Z antisynthetase autoantibody, FVC Z forced vital capacity, DLCO Z diffusing capacity for carbon monoxide, OP Z organizing
pneumonia, NSIP Z nonspecific interstitial pneumonia, UIP Z usual interstitial pneumonia.
a Data expressed as number (percent) unless otherwise specified.
Antisynthetase antibodies and myositis-associated ILD 1545(IQR 15e46 months). Fibrosis remained mild overall but was
statistically significantly worse at follow-up compared to
baseline (mean fibrosis score 16.1 vs. 13.9, respectively;
pZ 0.02). Ground glass was noted to be moderate initiallyFigure 1 Racial breakdown by ASA status.(mean ground glass score 8.1) and stable over time (mean
ground glass score 7.4, p Z 0.24). The total CT scan score
was mild overall, both on the initial scan (mean total CT
scoreZ 22.0) as well as on follow up study (mean follow up
total CT score Z 23.3, p Z 0.26).
Surgical lung biopsy results
Lung biopsy data was available for 42% of all participants.
The mean interval between the time of ILD diagnosis and
biopsy acquisition was 15 months (range 1e51 months) and
was not statistically different across all groups. The most
common biopsy finding was organizing pneumonia (OP)
(n Z 11, 34.4%), followed by usual interstitial pneumonia
(UIP) (n Z 10, 31.3%) and nonspecific interstitial pneu-
monia (NSIP) (nZ 10, 31.3%). There was 1 subject in whom
the biopsy subtype could not be identified and was officially
reported as “interstitial disease, non-specified”, labeled
“unclassifiable” in this paper. No significant difference was
noted between the various antisynthetase antibody groups
in regards to biopsy data. None of the eight anti-Jo1 posi-
tive participants who were biopsied demonstrated a UIP
pattern.
Table 3 Longitudinal regression model for carbon mon-
oxide diffusing capacity percent predicted (n Z 76).
Predictor Estimate  SE p-value
Age 0.24  0.23 0.29
Sex
Male (Reference)
Female 9.61  5.13 0.06
Race
African-American (Reference)
Caucasian/other 10.28  22.61 0.65
Antisynthetase antibody (ASA) status
ASA negative (Reference)
Anti-Jo1þ 13.79  9.32 0.14
Anti-PL-7 7.95  13.13 0.55
Anti-PL-12 12.29  10.94 0.26
Anti-EJ 6.15  30.37 0.84
Anti-OJ 22.66  15.64 0.15
Clinical subtype
Dermatomyositis (Reference)
Polymyositis 7.26  6.85 0.29
Overlap syndrome 14.82  6.43 0.02
Presenting symptom
Pulmonary (Reference)
Non-pulmonary 17.20  5.11 <0.01
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Pulmonary Physiology
Seventy-six participants (99% of the entire cohort) had both
initial and follow up pulmonary function test results avail-
able for analysis. The average follow up duration was 28
months (range 6e93 months). Participants with no demon-
strable antisynthetase antibodies had better FVC% over
time compared to those with anti-Jo1 and anti-OJ anti-
bodies after controlling for potential confounders (Table 2).
There was, however, no significant difference in the mean
DLCO% over time based on ASA status (Table 3). The FVC%
and DLCO% were significantly better over time for those
who presented with non-pulmonary symptoms compared to
those who presented with shortness of breath (p < 0.01,
95% CI 3.22 to 19.52 and p < 0.01, 95% CI 7.19 to 27.21,
respectively). The diagnosis of overlap syndrome was
associated with a worse FVC% and DLCO% over time
compared to DM alone (p Z 0.02, 95% CI 23.03 to 2.24
and p Z 0.02, 95% CI 27.43 to 2.22, respectively).
Chest CT scores
Forty-nine subjects (64%) had both initial and follow-up
chest CT results available for analysis. The average duration
between scans was 31 months (range 6e134 months). Par-
ticipants with no demonstrable antisynthetase antibodies
had lower total CT scores over time compared to those with
anti-Jo1 and anti-PL-12 antibodies after controlling for
potential confounders (Table 4).
Discussion
We retrospectively investigated the association between
specific antisynthetase antibody types and the clinicalTable 2 Longitudinal regression model for mean forced
vital capacity percent predicted (n Z 77).
Predictor Estimate  SE p-value
Age 0.16  0.18 0.37
Sex
Male (Reference)
Female 1.16  4.18 0.78
Race
African-American (Reference)
Caucasian/other 16.58  18.68 0.38
Antisynthetase antibody (ASA) status
ASA negative (Reference)
Anti-Jo1þ 16.41  7.67 0.03
Anti-PL-7 5.88  10.85 0.59
Anti-PL-12 8.45  9.01 0.35
Anti-EJ 22.24  22.21 0.32
Anti-OJ 26.40  12.94 0.04
Clinical subtype
Dermatomyositis (Reference)
Polymyositis 10.91  5.64 0.05
Overlap syndrome 12.63  5.30 0.02
Presenting Symptom
Pulmonary (Reference)
Non-pulmonary 11.37  4.16 <0.01characteristics of patients with autoimmune myositis
associated ILD. The power of this study is that it represents
one of the largest cohorts of ASA positive patients with MA-
ILD published to date.
Compared to previous population estimates, our cohort
was similar with respect to mean age at disease onset and
the ratio of men to women [20]. One unique feature of ourTable 4 Longitudinal regression model for total CT score
(n Z 65).
Predictor Estimate  SE p-value
Age 0.10  0.15 0.49
Sex
Male (Reference)
Female 3.92  3.45 0.26
Race
African-American (Reference)
Caucasian/other 13.29  14.94 0.37
Antisynthetase antibody (ASA) status
ASA negative (Reference)
Anti-Jo1þ 14.07  6.88 0.04
Anti-PL-7 12.14  9.28 0.19
Anti-PL-12 17.87  6.63 <0.01
Anti-EJ 10.79  19.35 0.58
Anti-OJ 10.13  9.71 0.30
Clinical subtype
Dermatomyositis (Reference)
Polymyositis 6.80  4.52 0.13
Overlap Syndrome 2.82  4.20 0.50
Presenting symptom
Pulmonary (Reference)
Non-pulmonary 6.50  3.39 0.06
Antisynthetase antibodies and myositis-associated ILD 1547cohort was the racial composition related to the fact that
our center cares for a larger number of African-American
patients than other comparable centers worldwide.
Despite a relative prevalence of autoantibodies similar to
published cohorts [2], we found that non-Jo1 anti-
synthetase autoantibodies were more prevalent in African-
American patients than in Caucasian patients. A similar
study of subjects with juvenile IIM also found statistically
significant differences in the racial distributions of myositis
associated and specific autoantibodies [21]. Additionally,
there is mounting evidence that racial expression of auto-
immunity varies resulting in important differences in clin-
ical phenotypes and outcomes [22]. Whether the racial
difference we found in antisynthetase autoantibody status
confers better or worse clinical outcomes for African-
Americans warrants further investigation.
The cohort as a whole demonstrated heterogeneity in
lung function [23], with few differences in FVC% and DLCO%
between antibody subtypes both at baseline and over time.
ASA negative participants did have a higher FVC% over time
compared to those with anti-Jo1 and anti-OJ antibodies but
this difference was not seen in the DLCO%. The clinical
significance of a better FVC% and DLCO% over time in those
who presented with non-pulmonary symptoms compared to
shortness of breath is unclear. Our study was not designed
to measure symptoms, quality of life, or mortality over
time. This finding, however, is consistent with previous
reports that suggested inferior long-term prognosis when
shortness of breath is the presenting symptom in anti-
synthetase syndrome [24]. Similarly the fact that those who
have an overlap syndrome had a worse FVC% and DLCO%
over time compared to those with DM is interesting but has
unknown clinical implications.
Expert radiologist CT scores reflected mild to moderate
levels of fibrosis and ground glass with mild overall disease
burden on imaging. The higher CT scores in those with anti-
Jo1 compared to those who were antibody negative is
internally consistent with the finding of worse lung function
over time in those subjects.
Although a lung biopsy generally is not required to
confirm ILD in patients with established myositis [25], over
40% of our subjects had lung biopsy specimens available for
review. While not statistically significant, the surgical lung
biopsy results of our patients suggest a potential difference
in pathologic effect between the antibody subtypes. There
were no instances of UIP by biopsy in our anti-Jo1 positive
cohort, which has not been described in previous series.
While a predominance of NSIP and OP on lung biopsy of anti-
Jo1 positive patients [13] and antibody negative patients
[26] has been reported previously, the high rate of UIP we
found in non-Jo1 ASA patients is unique.
Our study was limited by the fact that it was a retro-
spective, observational, single-center study of small sam-
ple size. This could have an unforeseen impact on patient
management or introduce a referral bias. All three of these
are difficulties frequently encountered in the study of a
rare condition. Further multicenter, collaborative efforts
will likely be required to generate a cohort of myositis-
associated ILD patients sufficiently large for adequately-
powered, prospective trials to be performed. Patients were
defined as ASA negative if they had ILD and clinically
diagnosed IIM in the absence of clinically available ASAs.Therefore it may be possible that some patients in the ASA
negative category have an ASA that is not yet easily
detectable. Not all patients had an initial CT scan available
for scoring, although all patients had a CT performed and
reviewed by our treating pulmonologist to establish or
confirm ILD. Given the high proportion of referrals not all
scans were performed at our center and it is not routine
practice to upload all images into our system. Follow-up CT
imaging was only performed when clinically indicated. This
could have introduced bias in the total CT scores over time.
Another limitation is that all patients were enrolled through
an outpatient treatment center, likely excluding the most
ill and rapidly progressive patients. There are reports that a
subset of patients, especially those with amyopathic der-
matomyositis and ILD, commonly do not live past the initial
phase of their illness [27e31]. The results of this study
cannot be generalized to those patients. Finally, the pa-
tients studied came to our Myositis Center through referral,
with many of them already started on corticosteroids or
other immune-modulating therapy prior to their initial PFTs
being performed. Thus “pre-treatment” and “post-treat-
ment” analysis was not performed in this population,
limiting the interpretation of the therapeutic response in
PFTs over time.
Conclusion
Our data suggest several potential, clinically relevant,
differences between the interstitial lung disease phenotype
seen in patients with varying antisynthetase antibody sub-
types. Further prospective study in a larger cohort is
needed to determine whether these apparent antibody-
specific differences in demographics and pathologic mani-
festations of disease will allow for the use of ASAs as bio-
markers to inform prognosis and/or tailor therapeutic
regimens for patients with myositis-associated interstitial
lung disease.
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